Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Myriad Genetics (MYGN) PT Raised to $26 at Morgan Stanley
November 8, 2017 8:43 AM ESTMorgan Stanley raised its price target on Myriad Genetics (NASDAQ: MYGN) to $26.00 (from $24.00) while maintaining a Underweight rating.
... More